<DOC>
	<DOC>NCT01899235</DOC>
	<brief_summary>A randomised open-label pilot study to assess the safety and efficacy of treatment with a drug eluting balloon alone in coronary de novo lesions). Elective patients requiring PCI to coronary de novo lesions in vessels 2.5 mm - 4.0 mm.</brief_summary>
	<brief_title>The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Angina, Stable</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Patient ≥ 18years old Stable angina symptoms Elective treatment to coronary lesion Reference vessel diameters of ≥ 2.5mm and ≤ 4.0 mm on visual inspection Left main stem lesion Bifurcation lesions Acute coronary syndrome (UAP, NSTEMI, STEMI) Cardiogenic shock Chronic total occlusion Additional lesions requiring PCI Platelet count ≤ 50 x 109/mm3 Left ventricular ejection fraction ≤ 30% Patient life expectancy less than 12 months Known allergies to aspirin, clopidogrel, prasugrel, heparin, stainless steel, intravenous contrast (severe), or paclitaxel Participation in another investigational drug or device study Patient unable to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>